Revolutionizing Prostate Cancer Detection: Dr. Heaton's Fireside Chat on the PSE Test

Category: PSE

Read Time: 4 Minutes

Last updated: 16 April 2024

What if we told you there’s a game-changing method for detecting prostate cancer that’s as simple as a routine blood test? In a recent fireside chat hosted by the Prostate Forum of Orange County, Dr. Robert Heaton, a board-certified pathologist, shares insights into a revolutionary advancement in prostate cancer screening: the EpiSwitch® Prostate Screening (PSE) test.

The PSE test offers a whole new level of clinical performance, detecting the presence or absence of prostate cancer with an impressive 94% accuracy

The power of precision: PSE’s innovative approach

Traditional methods like PSA tests have an accuracy of around 55%, but the PSE test offers a whole new level of clinical performance, detecting the presence or absence of prostate cancer with an impressive 94% accuracy. Dr. Heaton, the Medical Laboratory Director at Oxford BioDynamics’ Frederick CLIA Laboratory, delves into the PSE test’s innovative approach to cancer detection that sets it apart. Leveraging Oxford BioDynamics’ proprietary EpiSwitch platform, the PSE test evaluates epigenetic markers in blood cells to accurately detect the body's epigenetic regulatory response to cancer.

Revolutionizing diagnosis: the potential impact of the PSE

The PSE test’s class leading accuracy revolutionizes prostate cancer diagnosis, benefiting patients and doctors alike. Notably, the ability to accurately identify the presence or absence of cancer can assist in diagnostic decision-making and significantly reduce unnecessary and painful biopsies and their associated risks and costs. The PSE test empowers doctors and patients to navigate shared treatment decision-making with confidence.

Early detection is crucial to improving prostate cancer outcomes; when caught early, the five-year survival rate is nearly 100%

Spreading awareness: empowering men and their loved ones through education

Prostate cancer affects approximately 1 in 8 men. These are our spouses, fathers, brothers, grandfathers, and friends. Join us in spreading awareness about the PSE test and the importance of prostate cancer screening. Early detection is crucial to improving prostate cancer outcomes; when caught early, the five-year survival rate is nearly 100%. With the PSE test, we’re committed to helping men live longer, healthier, and happier lives. We extend our heartfelt appreciation to Dr. Heaton, the Prostate Forum of Orange County, and all those dedicated to advancing prostate cancer awareness, innovative screening methods, and treatments. Let’s continue to empower men to take charge of their prostate health!

To learn more about the PSE test, visit 94percent.com.

Stay In the Loop

Subscribe to receive our latest blog posts
Topics from groundbreaking discoveries to cutting-edge advancements and industry trends.

SHARE THIS POST

LEARN MORE ABOUT EPISWITCH® PROSTATE SCREENING TEST (PSE)

Detect the presence or absence of prostate cancer from blood with 94% accuracy. The PSE is a powerful screening test that identifies an individual’s current likelihood of having prostate cancer with just a routine blood test. The PSE is administered alongside or following a standard PSA test to significantly boost screening performance and reduce the number of men referred for unnecessary MRIs, biopsies, and treatments.

This powerful test is valuable for identifying individuals requiring biopsy and those suitable for active surveillance without further testing.

Learn About PSE
Immune checkpoint inhibitor antibody bound to white blood cell receptor to block inactivation by tumor cells